DCTH Delcath Systems Inc

$DCTH The current Estimated Primary Completion date for the Phase 2 MCC with Liver Cancer Dominant trial is December, 2026. Last update was June 1.

$DCTH Beware people…..the street wants to lull you into thinking $16 is the top. They want your shares so they can get ready for the next run to $25

$DCTH the more they push this down before earnings in 20 days, the more i will buy. I think this is a runner to 25-30 in next 3-6 months

$DCTH Remember my comments on Gerrard being conservative. If numbers come below second quarter price will be $14 to $15 range, if about the same as second quarter the price will be $17 to $19 range and if above second quarter will be $20 to $26 as all the analysts will be all over it and we know we got a winner. Let’s hope for at least the same as second quarter numbers.

$DCTH I just want to remind you a comment I made after the last earnings call. Gerrard always underestimated their prediction, but last call for the first time upped his predictions on sales for the company over what was estimated. This will be big this next quarter and is just a start as this company gains momentum. The base is $16 now and next quarter $20 to $24 are my predictions.

$DCTH Delcath qualifies as a fast-growing, higher-quality small-cap oncology candidate. Its strongest attributes are real commercial traction, exceptional gross margins, no debt, positive cash generation and meaningful indication-expansion potential. The reason to invest now is that HEPZATO has been commercially validated while the broader platform opportunity remains unproven and therefore incompletely valued.

$DCTH I agree with Wainwrights prediction unless there is a M & A that happens and if there is strong growth besides the breast cancer approval this estimate would be conservative.

$DCTH will have a presentation at the H.C. Wainwright 28thAnnual Global Investment Conference tomorrow. However, no webcast has been announced yet.

$DCTH Q3 is done and we are waaaay back on the pace for new site activations. That combined with the possible seasonality because of summerholidays might create a disaster for Delcath Q3...or not :)

$DCTH We should be getting an update on the Phase 2 trials pretty soon. The last one was June 1.

$DCTH If this is going to fill the gap from the Q2 earnings rally, it would have to go to around 12.50, because the stock jumped from there to over 14.00.